A Predictive Autoantibody Signature in Multiple Sclerosis

The researchers identified a distinct, stable immunogenic cluster (IC) in a subset of patients who developed MS. Individuals in this subset exhibited a characteristic autoantibody signature defined by a specific protein motif, which was present in serum years before their first clinical attack. This signature was also found in both the serum and cerebrospinal fluid of an independent validation cohort (UCSF ORIGINS) of patients presenting with their first clinical relapse. Notably, this MS-IC group displayed significantly higher levels of sNfL compared to both matched controls and MS patients who lacked this specific autoantibody profile, providing molecular evidence of an immunologically active prodromal phase of disease.

The identification of a stable, predictive autoantibody signature in the prodromal phase of MS offers a promising starting point for developing early diagnostic tools. Given the signature's high specificity and persistence, it may eventually serve as an antigen-specific biomarker to help identify high-risk individuals—such as those with clinically or radiologically isolated syndromes—years before they reach full clinical diagnosis. Furthermore, the similarity of the identified motif to proteins in common human pathogens, including Epstein-Barr virus, provides potential clues into the early immune-mediated triggers of MS, opening new avenues for understanding disease pathogenesis.